Factor IX Variants With Extended Half-Life for Hemophilia B
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Factor IX replacement therapies for hemophilia B are limited by the short half-life of Factor IX polypeptides, requiring frequent high-dose administrations and are costly, necessitating the development of variants with improved biological properties to reduce dosage frequency and increase therapeutic efficacy.
Innovation Solution
Development of Factor IX variants with specific amino acid substitutions at positions 338 and 410, enhancing coagulation activity and linked to half-life enhancers, such as albumin or Fc domains via cleavable linkers, to extend in vivo half-life and reduce administration frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Factor IX replacement therapy is administered frequently at high doses, then adequate Factor IX activity levels are maintained, but treatment cost increases and patient burden increases
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of Factor IX polypeptide, specifically introducing substitutions at positions 338 and/or 410, to enhance specific activity and extend half-life, thereby reducing the total dosage required while maintaining adequate activity levels
Solution Approach 2:
The patent employs composite materials by fusing Factor IX polypeptide with half-life enhancing portions such as albumin or immunoglobulin Fc regions, creating a hybrid molecule that combines the coagulation function of Factor IX with the prolonged circulation properties of the fused partner
2Quantity of substance
If Factor IX polypeptide with higher specific activity is developed, then less total polypeptide is required for replacement, but development complexity and cost increase
Solution Approach 1:
The patent systematically explores parameter changes by testing specific amino acid substitutions at positions 338 and 410, which are strategically located in the protease domain to maximize impact on specific activity while minimizing overall structural changes and development complexity
Solution Approach 2:
The patent utilizes composite materials by fusing Factor IX with well-characterized half-life enhancing portions like albumin or Fc regions, which have known pharmacokinetic properties, thereby reducing the uncertainty and complexity associated with developing entirely novel molecules
3Duration of action of moving object
If Factor IX half-life is extended through fusion with half-life enhancers, then administration frequency is reduced, but molecular weight and complexity increase
Solution Approach 1:
The patent applies composite materials by fusing Factor IX polypeptide with half-life enhancing portions such as albumin or immunoglobulin Fc regions, creating molecules with extended half-life that can be administered less frequently while managing the increased molecular complexity through rational design
Solution Approach 2:
The patent applies local quality by making targeted amino acid substitutions at specific positions (338 and/or 410) in the Factor IX sequence, thereby locally modifying the molecule to enhance specific activity without globally increasing complexity throughout the entire structure
Data Source
AI summary
This invention provides Factor IX variants, molecules comprising the variants, nucleic acids encoding the variants, compositions comprising the variants or the nucleic acids encoding the variants, and their use in methods for the modulation of hemostasis, for example in the prophylaxis or treatment of hemophilia B. The Factor IX variants have improved biological properties relative to other Factor IX variants and/or relative to wild-type Factor IX.